Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 47
Filtrar
Mais filtros










Filtros aplicados

Base de dados
Intervalo de ano de publicação
1.
Clín. investig. arterioscler. (Ed. impr.) ; 31(4): 152-159, jul.-ago. 2019. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-182709

RESUMO

Introducción: La participación monocitaria en la progresión aterosclerótica y sus efectos pro- o antiinflamatorios dependen de las subpoblaciones circulantes. El objetivo de este estudio es la caracterización de dichas subpoblaciones y su asociación con los factores de riesgo cardiovascular. Métodos: Estudio transversal que incluye 102 pacientes seleccionados; edad media: 65 años (rango 41-86 años), 69% varones. Se utilizó un panel de anticuerpos específicos frente a monocitos clásicos (Mon1, CD14+CD16− CD300e+HLADR+), intermedios (Mon2, CD14+CD16+CD300e+HLADR+) y no clásicos (Mon3, CD14-k-CD16+CD300e+HLADR+). Se establecieron tres grupos de estudio; grupo 1: sujetos asintomáticos con más de un factor de riesgo cardiovascular (n = 17); grupo 2: sujetos asintomáticos, pero con patología vascular por ecografía o microalbuminuria (n = 56); y grupo 3: pacientes con algún evento vascular aterotrombótico previo (n = 19). Asimismo, se calculó el riesgo cardiovascular mediante las escalas Framingham y REGICOR. Resultados: Se observó una asociación entre las subpoblaciones Mon1 y Mon2 y los grupos del estudio (ANOVA, p < 0,05), independiente de la edad y el sexo para los Mon2. Asimismo, las subpoblaciones Mon1 y Mon 2 se asociaron con eventos vasculares adversos (ß = 0,86, p = 0,02 y ß = 0,1 p = 0,002, respectivamente), siendo la asociación de Mon2 independiente de la edad y el sexo. Además, el porcentaje de Mon3 se asoció con la presencia de más de 2 factores de riesgo cardiovascular (ß=0,21, p=0,04) en el análisis univariante. Finalmente, se halló una correlación entre los niveles de Mon1 y Mon2 con el número de leucocitos (r = 0,7, p < 0,001 y r = 0,26 p < 0,01, respectivamente). Conclusiones: El análisis de subpoblaciones monocitarias es de gran interés clínico, ya que permite establecer un diferente perfil inflamatorio según los grupos de riesgo cardiovascular establecidos


Introduction: Monocytes play an important role in atherosclerotic progression having both pro and anti-inflammatory effects depending on different circulating monocyte subpopulations. The objective of this study is to characterize these subpopulations and their association with cardiovascular risk factors. Methods: Transversal study including 102 selected patients, mean age: 65 years-old (range 41-86), 69% males. A set of specific antibodies against classical monocytes (Mon1, CD14+CD16- CD300e+HLADR+), intermediate (Mon2, CD14+CD16+CD300e+HLADR+) and non-classical (Mon3, CD14-CD16+CD300e+HLADR+) was assayed. Three groups of patients were included: 17 asymptomatic with more than one cardiovascular risk factor (group 1), 56 subjects asymptomatic but with vascular pathology assessed by ultrasound or microalbuminuria (group 2) and 19 patients with a previous atherothrombotic event (group 3). The cardiovascular risk was determined by Framingham and REGICOR scores. Results: An association between study groups and the percentage of Mon1 and Mon2 was observed (ANOVA, p < .05), being independent of age and sex for Mon2. Likewise Mon1 and Mon2 subpopulations were associated with cardiovascular adverse events (ß = 0.86, p =.02 y ß = 0.1 p =.002, respectively), independently of age and sex in the case of Mon2. Moreover the percentage of Mon3 was associated with the presence of several cardiovascular risk factors (ß = 0.21, p = .04) in the univariate analysis. In addition, there was a correlation between the levels of Mon1 and Mon2 and leukocytes (r = 0.7, p < .001 and r = 0.26, p = .01, respectively). Conclusions: The analysis of monocyte subpopulations may be clinically useful to stratify the inflammatory profile related to the different cardiovascular risk groups


Assuntos
Humanos , Masculino , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Monócitos , Fatores de Risco , Doenças Cardiovasculares/diagnóstico , Aterosclerose/complicações , Estudos Transversais , Análise de Variância , Aterosclerose/diagnóstico , Aterosclerose/fisiopatologia , Grupos de Risco
3.
J. physiol. biochem ; 74(4): 579-589, nov. 2018. graf
Artigo em Inglês | IBECS | ID: ibc-179036

RESUMO

The main aim of this investigation was to study the regulatory roles of let-7b and miR-155-3p on the expression of inflammation-associated genes in monocytes, macrophages, and lipopolysaccharide (LPS)-activated macrophages (AcM). A second goal was to analyze the potential modulatory roles of different fatty acids, including oleic, palmitic, eicosapentaenoic (EPA), and docosahexaenoic (DHA), on the expression of these miRNAs in the three cell types. This hypothesis was tested in human acute monocytic leukemia cells (THP-1), which were differentiated into macrophages with 2-O-tetradecanoylphorbol-13-acetate (TPA) and further activated with LPS for 24 h. Monocytes, macrophages, and AcM were transfected with a negative control, or mimics for miR-155-3p and miR-let-7b-5p. The expression of both miRNAs and some proinflammatory genes was analyzed by qRT-PCR. Interestingly, let-7b mimic reduced the expression of IL6 and TNF in monocytes, and SERPINE1 expression in LPS-activated macrophages. However, IL6, TNF, and SERPINE1 were upregulated in macrophages by let-7b mimic. IL6 expression was higher in the three types of cells after transfecting with miR-155-3p mimic. Similarly, expression of SERPINE1 was increased by miR-155-3p mimic in monocytes and macrophages. However, TLR4 was downregulated by miR-155-3p in monocytes and macrophages. Regarding the effects of the different fatty acids, oleic acid increased the expression of let-7b in macrophages and AcM and also increased the expression of miR-155 in monocytes when compared with DHA but not when compared with non-treated cells. Overall, these results suggest anti- and proinflammatory roles of let-7b and miR-155-3p in THP-1 cells, respectively, although these outcomes are strongly dependent on the cell type. Noteworthy, oleic acid might exert beneficial anti-inflammatory effects in immune cells (i.e., non-activated and LPS-activated macrophages) by upregulating the expression of let-7b


No disponible


Assuntos
Humanos , Ácidos Graxos não Esterificados/metabolismo , Macrófagos/metabolismo , MicroRNAs/metabolismo , Monócitos/metabolismo , Diferenciação Celular , Ácidos Docosa-Hexaenoicos/metabolismo , Regulação para Baixo , Interleucina-6/agonistas , Interleucina-6/antagonistas & inibidores , Interleucina-6/genética , Lipopolissacarídeos/toxicidade , Ativação de Macrófagos , MicroRNAs/química
4.
Gastroenterol. hepatol. (Ed. impr.) ; 41(7): 423-431, ago.-sept. 2018. tab
Artigo em Inglês | IBECS | ID: ibc-180622

RESUMO

BACKGROUND: Granulocyte and monocyte apheresis is the main non-pharmacological treatment for inflammatory bowel disease (IBD), but we do not know how well accepted it is by patients in our setting. AIM: To determine how granulocyte and monocyte apheresis is perceived by patients in clinical practice in Spain. METHODS: Outpatients treated with granulocyte and monocyte apheresis in five IBD Units in Spain were asked to fill in a 14-item questionnaire. RESULTS: Fifty-two patients completed the questionnaire (88% ulcerative colitis, 12% Crohn's disease; 44% female; age 35 years [IQR 23-51]). Granulocyte and monocyte apheresis was generally well tolerated and well accepted. Very few of the participants regarded the length of the sessions as a limitation. The gastrointestinal symptoms, however, were a frequent concern, both in terms of attending to receive treatment and during the sessions. Overall, 44% were satisfied with the treatment effectiveness. Sixty percent (60%) claimed to be satisfied with the therapy overall, but this was influenced by the patients' clinical response to the therapy. Eighty-two percent (82%) of participants said they would agree to be treated with this technique again in the future, regardless of the response to the treatment. CONCLUSIONS: Granulocyte and monocyte apheresis is well tolerated and accepted by patients with IBD. Although we found no significant differences according to type of IBD or apheresis regimen, patient perception was affected by clinical effectiveness


INTRODUCCIÓN: La leucocitoaféresis constituye el principal tratamiento no farmacológico para la enfermedad inflamatoria intestinal (EII), pero no conocemos su grado de aceptación por los pacientes en nuestro entorno. OBJETIVO: Conocer la percepción de los pacientes sobre la leucocitoaféresis en la práctica clínica en España. MÉTODOS: Se ofreció un cuestionario de 14 preguntas a los pacientes ambulatorios tratados con leucocitoaféresis en 5 unidades de EII en España. RESULTADOS: Cincuenta y dos pacientes respondieron el cuestionario (88% colitis ulcerosa, 12% enfermedad de Crohn; 44% mujeres, 35 años [RIQ: 23-51]). La leucocitoaféresis fue bien tolerada de forma global y con un alto grado de aceptación. La mayoría de pacientes no percibía la duración de las sesiones como una limitación. En cambio, los síntomas digestivos eran una preocupación habitual, tanto para acudir al tratamiento como durante las sesiones. Un 44% estaban satisfechos con la efectividad del tratamiento. El 60% contestaron que estaban satisfechos con la técnica de forma global, pero esto estaba influenciado por la respuesta clínica que habían experimentado. Un 82% estarían dispuestos a ser tratados de nuevo con la técnica, independientemente de la respuesta al tratamiento. CONCLUSIONES: La leucocitoaféresis es una técnica bien tolerada y aceptada por los pacientes con EII. A pesar de que no encontramos diferencias según el tipo de EII o la pauta de tratamiento, sí encontramos una percepción diferente según la efectividad de la técnica


Assuntos
Humanos , Masculino , Feminino , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Doenças Inflamatórias Intestinais/terapia , Leucaférese/métodos , Monócitos , Aceitação pelo Paciente de Cuidados de Saúde , Satisfação do Paciente , Granulócitos , Anti-Inflamatórios/uso terapêutico , Antirreumáticos/uso terapêutico , Terapia Combinada , Doenças Inflamatórias Intestinais/sangue , Doenças Inflamatórias Intestinais/tratamento farmacológico , Inquéritos e Questionários
5.
Clin. transl. oncol. (Print) ; 20(4): 476-483, abr. 2018. tab, graf
Artigo em Inglês | IBECS | ID: ibc-171640

RESUMO

Background. Nowadays, neoadjuvant chemotherapy (nCT) in breast cancer is more and more standardized, not only in advanced tumours but also in those for which there is an attempt to achieve breast-conserving surgery. In literature, we can find evidences of the relationship between several types of tumours and systemic inflammatory response. Our objective is to analyse the prognostic value of blood parameters (lymphocytes, neutrophils, monocytes, lymphocyte-to-monocyte ratio (LMR), neutrophil-to-monocyte ratio (NMR) and neutrophil-to-lymphocyte ratio (NLR) in breast cancer (BC) patients treated with nCT. Methods. A retrospective cohort of 150 breast cancer patients treated with nCT and subsequently with surgery was analysed. Data about the patients, histology, response to chemotherapy and peripheral blood values of lymphocytes, monocytes and neutrophils was collected, and used to calculate the LMR, NMR and NLR. Univariate and multivariate analyses were performed for the variables to see the relationship of the ratios to disease-free survival (DFS) and overall survival (OS). Results. Patients with high LMR (≥5.46) and low NLR (<3.33) were associated with a lower percentage of relapse (P = 0.048 and P = 0.015, respectively) and, above all, NLR was associated with a better survival (P = 0.024), being those factors that predict a good progress. Conclusion. High LMR and low NLR can be considered as favourable prognostic factors in BC patients treated with nCT (AU)


No disponible


Assuntos
Humanos , Feminino , Neoplasias da Mama/patologia , Antineoplásicos/farmacocinética , Linfócitos , Monócitos , Neutrófilos , Neoplasias da Mama/tratamento farmacológico , Terapia Neoadjuvante/estatística & dados numéricos , Estudos Retrospectivos , Biomarcadores Tumorais/análise , Prognóstico
6.
Clin. transl. oncol. (Print) ; 19(10): 1175-1182, oct. 2017.
Artigo em Inglês | IBECS | ID: ibc-166149

RESUMO

The immune system regulates angiogenesis in cancer by way of both pro- and antiangiogenic activities. A bidirectional link between angiogenesis and the immune system has been clearly demonstrated. Most antiangiogenic molecules do not inhibit only VEGF signaling pathways but also other pathways which may affect immune system. Understanding of the role of these pathways in the regulation of immunosuppressive mechanisms by way of specific inhibitors is growing. Renal cell carcinoma (RCC) is an immunogenic tumor in which angiogenesis and immunosuppression work hand in hand, and its growth is associated with impaired antitumor immunity. Given the antitumor activity of selected TKIs in metastatic RCC (mRCC), it seems relevant to assess their effect on the immune system. The confirmation that TKIs improve cell cytokine response in mRCC provides a basis for the rational combination and sequential treatment of TKIs and immunotherapy (AU)


No disponible


Assuntos
Humanos , Carcinoma de Células Renais/tratamento farmacológico , Carcinoma de Células Renais/imunologia , Imunoterapia/métodos , Imunoterapia , Inibidores da Angiogênese/administração & dosagem , Inibidores da Angiogênese/imunologia , Imunomodulação , Imunomodulação/imunologia , Células Dendríticas , Células Dendríticas/imunologia , Monócitos
7.
Med. oral patol. oral cir. bucal (Internet) ; 22(1): e1-e6, ene. 2017. ilus, graf
Artigo em Inglês | IBECS | ID: ibc-159760

RESUMO

Background: It is now well established that IL-4 has a central role in the development of monocytes to multinucleated giant cells (MGCs) by inducing the expression of integrins on the surface of monocytes. The aim of this study was to investigate the potential role of IL-4 in induction of β5 integrin expression in the peripheral blood samples of patients with giant cell granuloma. Material and Methods: Monocytes were isolated from peripheral blood samples of patients with central giant cell granuloma (CGCG) and healthy controls using human Monocyte Isolation Kit II. Isolated monocytes were then cultured in the absence or presence of IL-4 (10 and 20 ng/mL), and following RNA extraction and cDNA synthesis, Real-time PCR was performed to determine the level of β5 integrin expression. The formation of CGCGs and morphological analyses were done under light microscopy. For confirmation of CGCGs, immunocytochemistry technique was also carried out by anti-RANK (receptor-activator of NF-κB ligand) antibody. Results: In both patient and control groups, β5 levels were significantly enhanced by increasing the IL-4 dose from 10 to 20 ng/mL. In addition, these differences were significant between patient and control groups without IL-4 treatment. On the other hand, the number of cells which expressed RANK and therefore the number of giant cells were significantly higher in the patient group in comparison to controls, as assessed by immunohistochemistry evaluations. Conclusions: In this study, we showed an elevation in the expression levels of β5 integrin when stimulated by IL-4. It is strongly indicated that this integrin acts as an important mediator during macrophage to macrophage fusion and development of giant cells (AU)


No disponible


Assuntos
Humanos , Carcinoma de Células Gigantes/patologia , Interleucina-4/farmacocinética , Neoplasias Mandibulares/patologia , Granuloma de Células Gigantes/patologia , Monócitos/patologia , Cadeias beta de Integrinas/análise , Células Gigantes/patologia , Leucócitos Mononucleares/patologia , Estudos de Casos e Controles
8.
Arch. esp. urol. (Ed. impr.) ; 69(9): 627-635, nov. 2016. graf, tab
Artigo em Inglês | IBECS | ID: ibc-157667

RESUMO

Objectives: In this study we compared neutrophil-to-lymphocyte ratio(NLR) and neutrophilto-monocyte ratio(NMR) between patients with prostate cancer after first transrectal ultrasound(TRUS)- guided biopsy and patients with benign prostate hyperplasia(BPH) after second TRUS-guided biyopsy. Methods: A total of 224 patients who underwent multi (≥12)-core TRUS-guided biopsy at our clinic for elevated PSA or abnormal digital rectal examination in between January 2008 and March 2015 were retrospectively analyzed. There were 2 groups. Group1 consisted of 146 patients with a diagnosis of prostate cancer after the first TRUSguided biyopsy and group 2 consisted of 78 patients with a diagnosis of benign prostate hyperplasia after second TRUS-guided biyopsy. Age, PSA, NLR and NMR values were compared between the two groups. Results: There were no statistically significant correlation between PSA and NLR( p=0.46). The mean of age, PSA, NLR, NMR values in the group 1 and 2 were respectively 64.6±7.7 and 61.6±6.9, 6.5±1.9 and 5.3±1.2, 2.8±1.5 and 2.3±1.1, 9.2±3.9, 8.1±2.9 (p=0.03, p=0.001, p=0.012 and p=0.30). The mean PSA, NLR ,NMR values of the group 1 were significantly higher than those in group 2 (p=0.002). Gleason grade and pathological stage were significantly increases as NLR increases. Conclusion: NLR and NMR in patients with BPH after second TRUS-guided biopsy were lower than that of those with a diagnosis of prostate cancer after the first TRUS-guided biopsy.White blood test subtypes can be considered for the decision to perform a second TRUS guided biopsy in patients with previous negative biopsy with persistently elevated PSA (AU)


Objetivo: En este estudio comparamos la relación de neutrófilos/linfocitos (RNL) y de neutrófilos/ monocitos (RNM) en pacientes con cáncer de próstata después de la primera biopsia transrectal ecodirigida y pacientes con hiperplasia benigna de próstata (HBP) después de la segunda biopsia. Métodos: Analizamos retrospectivamente un total de 224 pacientes con PSA elevado o tacto rectal anormal que fueron sometidos a biopsias múltiples (≥12) guiadas por ecografía transrectal en nuestra consulta entre enero del 2008 y marzo del 2015. Había 2 grupos. El Grupo 1 incluía 146 pacientes con el diagnóstico de cáncer de próstata después de la primera biopsia y el grupo 2, 78 pacientes con el diagnóstico de HBP después de la segunda biopsia transrectal ecodirigida. Se compararon la edad, el PSA, y los valores de RNL y RNM entre los grupos. Resultados: No había correlación estadísticamente significativa entre PSA y RNL (p=0,46). Los valores medios de edad, PSA, RNL y RNM en los grupos 1 y 2 fueron respectivamente 64,6±7,7 y 61,6±6,9, 6,5±1,9 y 5,3±1,2, 2,8±1,5 y 2,3±1,1, 9,2±3,9, 8,1±2,9 (p=0,03, p=0,001, p=0,012 y p=0,30). Los valores de las medias de PSA, RNL y RNM del grupo 1 eran significativamente mayores que los del grupo 2 (p=0,002). El grado de Gleason y el estadio patológico aumentaban significativamente al aumentar la RNL. Conclusion: La RNL y la RNM eran significativamente menores en pacientes con HBP después de segunda biopsia transrectal ecodirigida en comparación con los que fueron diagnosticados de cáncer de próstata después de la primera biopsia. El test de subtipos de células blancas puede ser considerado para la toma de decisión de realizar una segunda biopsia transrectal ecodirigida en pacientes con biopsia previa negativa y elevación persistente de PSA (AU)


Assuntos
Humanos , Masculino , Hiperplasia Prostática/sangue , Neoplasias da Próstata/sangue , Biópsia , Contagem de Células Sanguíneas , Neutrófilos , Monócitos , Linfócitos , Estudos Retrospectivos , Antígeno Prostático Específico/análise
9.
Allergol. immunopatol ; 44(4): 359-367, jul.-ago. 2016. tab, graf
Artigo em Inglês | IBECS | ID: ibc-154439

RESUMO

Background: There is no conclusive evidence regarding the effect of fasting on different features in asthmatic patients. In the present study, the effect of Ramadan fasting in asthmatic patients and healthy control was studied. Methods: Haematological indices, inflammatory mediators, pulmonary function tests (PFT) and respiratory symptoms were evaluated in 15 asthmatic patients compared to 14 healthy matched control group before and after the one-month fasting period in Ramadan. The change in each parameter from the beginning to the end of Ramadan was calculated and referred to as ‘variation during Ramadan’. Results: The values of MCH, MCHC in both groups and monocyte counts in asthmatic patients, were significantly increased but platelet count was reduced in asthmatic and controls respectively compared to pre-Ramadan fasting period (P<0.05 to 0.001). Serum hs-CRP level in control and asthmatic groups was significantly reduced after Ramadan fasting month (P<0.001 for both groups). PFT values after Ramadan fasting month in both groups were non-significantly higher compared to pre-fasting values except FVC. Respiratory symptoms in asthmatic patients were non-significantly but wheeze-o was significantly reduced after Ramadan fasting period in asthma group (P<0.05). There was no significant difference in variations of different parameters during Ramadan fasting period between two groups, although reduction of hs-CRP in asthmatic group was non-significantly higher than control group. Conclusion: These results show that Ramadan fasting period has no negative impact on asthma and may have some positive effect on asthma severity with regard to reduction of hs-CRP concentration and chest wheeze (AU)


No disponible


Assuntos
Humanos , Masculino , Feminino , Adulto , Asma/dietoterapia , Asma/imunologia , Asma/patologia , Proteína C-Reativa/análise , Proteína C-Reativa/imunologia , Mediadores da Inflamação/imunologia , Monócitos/imunologia , Exames Médicos/métodos , Técnicas de Laboratório Clínico/métodos , Transtornos Respiratórios/complicações , Transtornos Respiratórios/imunologia
10.
Rev. clín. esp. (Ed. impr.) ; 216(3): 135-145, abr. 2016. tab, ilus
Artigo em Espanhol | IBECS | ID: ibc-150041

RESUMO

El síndrome antifosfolipídico obstétrico es una alteración autoinmune adquirida que asocia diversas complicaciones obstétricas, en ausencia de historia trombótica previa, junto con la existencia de anticuerpos antifosfolipídicos dirigidos contra fosfolípidos, proteínas denominadas cofactores o contra complejos fosfolípidos-cofactor. Aunque las complicaciones obstétricas se han relacionado con sus propiedades procoagulantes, estudios anatomopatológicos en placentas humanas han demostrado su capacidad proinflamatoria vía sistema del complemento-citocinas proinflamatorias. No hay acuerdo general sobre cuál es el perfil de anticuerpos antifosfolipídicos (categoría de laboratorio) que confiere más riesgo obstétrico, aunque las denominadas categorías I y IIa son las mejores candidatas. El tratamiento combinado con dosis bajas de aspirina y heparina consigue buenos resultados obstétricos y maternos. Se revisan también las posibilidades terapéuticas en los casos refractarios. La evolución a otras enfermedades autoinmunes es baja. Se comenta brevemente el denominado síndrome antifosfolipídico obstétrico incompleto, también conocido como síndrome de morbilidad obstétrica asociada a anticuerpos antifosfolipídicos (AU)


Obstetric antiphospholipid syndrome is an acquired autoimmune disorder that is associated with various obstetric complications and, in the absence of prior history of thrombosis, with the presence of antiphospholipid antibodies directed against other phospholipids, proteins called cofactors or PL-cofactor complexes. Although the obstetric complications have been related to the procoagulant properties of antiphospholipid antibodies, pathological studies of human placenta have shown the proinflammatory capacity of antiphospholipid antibodies via the complement system and proinflammatory cytokines. There is no general agreement on which antiphospholipid antibodies profile (laboratory) confers the greatest obstetric risk, but the best candidates are categories I and IIa. Combined treatment with low doses of aspirin and heparin achieves good obstetric and maternal outcomes. In this study, we also review the therapeutic possibilities in refractory cases, although the likelihood of progressing to other autoimmune diseases is low. We briefly comment on incomplete obstetric antiphospholipid syndrome, also known as antiphospholipid antibody-mediated pregnancy morbidity syndrome (AU)


Assuntos
Humanos , Feminino , Síndrome Antifosfolipídica/complicações , Síndrome Antifosfolipídica/imunologia , Síndrome Antifosfolipídica/terapia , Anticorpos Antifosfolipídeos/uso terapêutico , Aborto , Pré-Eclâmpsia/diagnóstico , Pré-Eclâmpsia/terapia , Complicações na Gravidez/epidemiologia , Complicações na Gravidez/imunologia , Placenta/anatomia & histologia , Placenta/imunologia , Inquéritos de Morbidade , Monócitos/imunologia , Monócitos/patologia , Síndrome Antifosfolipídica/epidemiologia , Síndrome Antifosfolipídica/prevenção & controle , Indicadores de Morbimortalidade , Período Pós-Parto/imunologia
11.
Arch. med. deporte ; 32(167): 136-143, mayo-jun. 2015. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-140261

RESUMO

Introducción: Las pacientes con fibromialgia (FM) presentan una alteración de la retroalimentación entre la respuesta inflamatoria y la respuesta de estrés. La hipótesis anti-inflamatoria del ejercicio hace a éste especialmente interesante como ayuda terapéutica en el tratamiento de patologías inflamatorias tales como la FM. No obstante, los efectos del ejercicio pueden ser diferentes en personas con estados inflamatorios alterados respecto a personas sanas. Para testar esta hipótesis, el objetivo ha sido conocer los efectos de una sesión de ejercicio sobre la respuesta inflamatoria y de estrés en pacientes con FM comparados con un grupo control de personas sanas. Métodos: 8 mujeres diagnosticadas con FM y 8 mujeres sanas fueron incluidas en el estudio. Tanto en situación basal como tras una sesión de ejercicio sobre cicloergómetro (45 min al 55% de VO2max) se determinó por ELISA la concentración circulante de serotonina y por Bioplex LUMINEX la liberación espontánea de IL-18, IL-6 e IL-10 por monocitos, así como la capacidad fagocítica y microbicida de neutrófilos. Resultados y conclusiones: Las pacientes con FM presentan menores niveles circulantes de serotonina y un estado activado de monocitos y neutrófilos. Mientras que el ejercicio aumentó la liberación espontánea de las citoquinas IL-18, IL-6 e IL-10 en las mujeres sanas, se observó, contrariamente, un descenso en la liberación de las mismas por los monocitos de pacientes con FM. Un efecto dual también fue observado en los niveles circulantes de serotonina (elevando los niveles de las pacientes con FM). Sin embargo, en ambos grupos el ejercicio indujo una estimulación de la capacidad fagocítica-microbicida de los neutrófilos. El ejercicio agudo moderado mejora el estado inflamatorio de las pacientes con FM sin perjudicar su capacidad de defensa frente a patógenos. También podemos concluir que la capacidad antiinflamatoria del ejercicio se manifiesta fundamentalmente frente a estados inflamatorios elevados o desregulados (AU)


Introduction: Patients with fibromyalgia (FM) have an altered feedback between the inflammatory response and the stress response. The anti-inflammatory hypothesis of exercise makes this particularly interesting as a therapeutic aid in the treatment of inflammatory diseases such as FM. However, the effects of exercise may be different in people with altered inflammatory conditions regarding the effects in healthy people. To test this hypothesis, the aim of this investigation was to determine the effects of an acute exercise session on the inflammatory response and the stress response in FM patients compared to those observed in a control group of healthy people. Methods: 8 women diagnosed with FM and 8 healthy women were included in the investigation. Both in basal condition and immediately after a single session of moderate exercise (cycling for 45 min at 55% of VO2max) the circulating level of serotonin (by ELISA) and the spontaneous release of IL-18, IL-6, and IL-10 by isolated monocytes from blood were determined by Bioplex LUMINEX. Phagocytic and microbicidal capacity against C. albicans by neutrophils were also evaluated. Results and conclusions: FM patients have lower circulating levels of serotonin and an activated state of monocytes and neutrophils. While the exercise increased the spontaneous release of IL-18, IL-6, and IL-10 in healthy women, the exercise decreased this release by the monocytes from FM patients. A dual effect was also observed in the levels of circulating serotonin (in this case by raising levels of patients with FM). However, in both groups, exercise induced a stimulation of the phagocyticmicrobicidal capacity of neutrophils. The acute moderate exercise improves the inflammatory status of FM patients without impairing its ability to defend against pathogens. We can also conclude that the anti-inflammatory capacity of exercise is manifested primarily against high or dysregulated inflammatory conditions (AU)


Assuntos
Feminino , Humanos , Pessoa de Meia-Idade , Exercício Físico/fisiologia , Terapia por Exercício/tendências , Terapia por Exercício , Inflamação/terapia , Neutrófilos/fisiologia , Monócitos/fisiologia , Citocinas/fisiologia , Estilo de Vida , Voluntários Saudáveis/estatística & dados numéricos , Ensaio de Imunoadsorção Enzimática/instrumentação , Ensaio de Imunoadsorção Enzimática/métodos , Ensaio de Imunoadsorção Enzimática , Grupos Controle , Antropometria/métodos , Inquéritos e Questionários/normas , Inquéritos e Questionários
12.
Nutr. hosp ; 30(1): 113-117, jul. 2014. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-143750

RESUMO

El objetivo de este trabajo es evaluar la actividad antiinflamatoria de un extracto de naturaleza polifenólica de huesos de oliva. Material y métodos: Se incubó la línea celular THP1- XBlue-CD14 (invivogen), 80.000 células/pocillo, provocando inflamación (activación de NF-kb) mediante 0.1 µg/ml LPS (lipopolisacárido de E. coli) durante 24 horas. Se evaluó la presencia del extracto (10 y 50 mg/l, concentraciones bioseguras) durante 2 horas a 37 ºC, previa (efecto preventivo) y posterior a la activación proinflamatoria (efecto terapéutico) y se cuantificó colorimétricamente la actividad de fosfatasa alcalina, que se expresa bajo el control del promotor del factor transcripcional de NF-kb. Se evalúa el % actividad de NF-kb en efecto preventivo y terapéutico respecto a cultivos control de células con LPS y sin extracto añadido, que se consideran 100% de NF-kb. Resultados: La capacidad antiinflamatoria preventiva del extracto a 50 mg/l es del 25,5% (IC 95% 16,8-34,2) y el efecto terapéutico del 34,9% (IC 95% 25,3-44,4) para la misma concentración, no presentando actividad significativa a 10 mg/l. Conclusión: Se muestra una actividad de los polifenoles extraídos de los huesos de aceitunas, tanto preventivo de la inflamación como terapéutico de eliminación de la inflamación a través de la inhibición del factor NF-kB previamente activado por LPS a concentraciones de 50 mg/l de polifenoles que previamente se han mostrado seguras (AU)


The aim of this study was to assess the anti-inflammatory activity of a polyphenolic extract from olive pits. Material and methods: The THP1-XBlue-CD14 (invivogen) cellular line, 80,000 cells/well, was incubated and inflammation (activation of NF-kb) was produced with 0.1 mg/mL of LPS (lipopolysaccharide from E. coli) for 24 hours. We assessed the presence of the extract (10 and 50 mg/L, biologically safe concentrations) for 2 hours at 37º C, before (preventive effect) and after (therapeutic effect) the proinflammatory activation, and the activity of alkaline phosphatase, which is expressed under the control of the NF-kb transcriptional factor, was quantified by colorimetry. The percentage of activity of NF-kb as preventive effect and therapeutic effect was assessed by comparing it to control cultures of cells with LPS and without extract, which are considered 100% of NF-kb. Results: The preventive anti-inflammatory capacity of the extract at 50 mg/L was 25.5% (95% CI: 16.8-34.2) and the therapeutic effect 34.9% (95% CI: 25.3-44.4) for the same concentration, without any significant activity at 10 mg/L. Conclusion: An activity of polyphenols extracted from olive pits is shown, both in preventing inflammation and therapeutically eliminating inflammation through inhibition of NF-kB factor previously activated by LPS at concentrations of 50 mg/L of polyphenols, which previously haven been shown to be safe (AU)


Assuntos
Humanos , Anti-Inflamatórios/farmacocinética , Polifenóis/farmacocinética , Monócitos , Inflamação/tratamento farmacológico , Extratos Vegetais/farmacocinética , Olea , Lipopolissacarídeos/análise , Mediadores da Inflamação
13.
Clín. investig. arterioscler. (Ed. impr.) ; 26(3): 131-137, mayo-jun. 2014. ilus, tab
Artigo em Inglês | IBECS | ID: ibc-124895

RESUMO

Introduction: In vitro ceramide-enriched LDL (CER-LDL) reproduces most of the properties of electronegative LDL (LDL(-)), a heterogeneous subfraction of LDL found in plasma. LDL(-) comprises several modifications of LDL and has an increased content in ceramide (CER). It promotes cytokine release in monocytes through CD14 and TLR4. CER-LDL also induces cytokine release in these cells but the mechanism is unknown. Aim To evaluate TLR4 andCD14 as the putative receptors involved in cytokine release induced by CER-LDL. Methods CER-LDL was obtained by incubating native LDL with CER-enriched liposomes. CER content in CER-LDL was assessed by thin layer chromatography of lipid extracts. CER-LDL and LDL(-) were incubated for 20 h with human monocytes in the presence or absence of a TLR4 signaling inhibitor. Both LDLs were also incubated with two human monocytic cell lines, normal and THP1 overexpressing CD14 (THP1-CD14) cells. The release of IL-6, IL-10 and MCP-1 was evaluated by ELISA in culture medium. Results: The release of IL-6, IL-10 and MCP-1 induced by CER-LDL in monocytes was inhibited by VIPER (90% inhibition), a specific TLR4 inhibitor. The cytokine release induced by contrast, the induction of cytokine release in THP1-CD14 was high and dependent on the CER content in LDL. Conclusion: CER-LDL induces IL-6, IL-10 and MCP-1 release through the activation of CD14 and TLR4 in monocytes, reproducing the behavior of LDL(-). The increased content of CER in LDL(-) is then related to the inflammatory action of LDL(-)


Introducción: La LDL enriquecida in vitro en ceramida (CER-LDL) reproduce varias características atribuidas a la LDL electronegativa (LDL(-)), subfracción heterogénea de LDL presente en circulación que induce la liberación de citoquinas en monocitos mediante CD14 y TLR4. La CER-LDL estimula también la liberación de citoquinas en monocitos, aunque el mecanismo se desconoce. Objetivo: Evaluar si CD14-TLR4 son receptores activados por la CER-LDL para inducir la liberación de citoquinas. Material y métodos: La CER-LDL se obtuvo in vitro mediante incubación de LDL nativa con liposomas enriquecidos en CER. El contenido en CER de la CER-LDL fue evaluado mediante cromatografía en capa fina. La CER-LDL y la LDL(−) fueron incubadas 20 h con monocitos humanos en presencia o ausencia de un inhibidor de la señalización de TLR4. También se incubaron con 2 líneas de monocitos humanos, THP1 y THP1, que sobreexpresan CD14 (THP1-CD14). Se evaluaron IL-6, IL-10 y MCP-1 en todos los sobrenadantes celulares mediante ELISA. Resultados: La liberación de IL-6, IL-10 y MCP-1 inducida por la CER-LDL en monocitos fue inhibida mediante VIPER (90% de inhibición), inhibidor específico de TLR4. Las citoquinas liberadas por la CER-LDL fueron escasas en THP1, células que presentan baja expresión de CD14. Las citoquinas liberadas por la CER-LDL en THP1-CD14 fueron superiores y dependientes del contenido en CER de la LDL. Conclusión: La LDL-CER induce IL-6, IL-10 y MCP-1 a través de la activación de CD14-TLR4 en monocitos, mimetizando a la LDL(-). La acción inflamatoria de la LDL(-) está relacionada con su contenido aumentado en CER


Assuntos
Humanos , Ceramidas/farmacocinética , Citocinas , Receptor 4 Toll-Like , Receptores de Lipopolissacarídeos , Lipoproteínas LDL/farmacocinética , Monócitos , Cromatografia/métodos
15.
Clín. investig. arterioscler. (Ed. impr.) ; 23(4): 160-167, jul.-ago. 2011. ilus, tab
Artigo em Espanhol | IBECS | ID: ibc-92900

RESUMO

Introducción Recientemente nuestro grupo ha demostrado que ezetimibe, un inhibidor específico de la absorción intestinal, es capaz de inhibir la inflamación vascular en un modelo de arteriosclerosis en conejo. Nuestro objetivo ha sido investigar el efecto de ezetimibe sobre la adhesión y la migración de monocitos humanos THP-1, así como la participación de la vía de señalización de las proteincinasas activadas extracelularmente (p44/p42ERK1/2) sobre el efecto observado. Material y métodos La adhesión se valoró como la capacidad de las células THP-1 para unirse a placas de cultivo, y la migración se determinó con el empleo de cámaras de quimiotaxis. La expresión de moléculas de adhesión se cuantificó mediante citometría de flujo, y la activación de p44/p42ERK1/2 se estudió mediante Western Blot. Resultados La adhesión y la migración de los monocitos THP-1 inducidas con PMA o MCP-1, respectivamente, se inhibió de forma dependiente de la dosis al preincubar las células con ezetimibe. Además, el tratamiento con ezetimibe inhibió la expresión de las integrinas CD11a y CD11b, así como la fosforilación de p44/p42ERK1/2 (la forma activa) inducida por MCP-1. Más del 90% de las células (evaluadas mediante azul tripán) eran viables tras 1 ó 2 días de exposición a ezetimibe. Conclusiones Nuestros resultados indican que ezetimibe, además de su actividad hipolipemiante, puede inhibir el proceso de adhesión y migración de los monocitos. Parece que el bloqueo de la ruta de señalización de las MAPK p44/p42ERK1/2 podría estar implicado en el efecto observado (AU)


Introduction: Recently, our group has demonstrated that ezetimibe, a specific inhibitor of intestinal absorption, is able to inhibit vascular inflammation in a rabbit model of atherosclerosis. In this study, we investigated the effect of ezetimibe on the adhesion and migration of human THP-1 monocytes in vitro. We also studied the involvement of the MAP kinase signaling pathway,p44/p42ERK1/2, as a potential mechanism responsible for the observed effect. Material and methods: Adhesion of THP-1 monocytes was measured as the ability of cells tobind to plates. Migration was studied using two-compartment chambers. The expression of adhesion molecules was assessed by flow cytometry. Activation of p44/p42ERK1/2 was measured by Western Blot. Results: Preincubation of THP-1 monocytes with ezetimibe prevented PMA-induced adhesion and MCP-1-induced migration in a dose-dependent manner. Preincubation of THP-1 monocytes with ezetimibe also inhibited the expression of the integrins CD11a and CD11b, as well asphosphorylation of p-p44/p42ERK1/2 (the active form) induced by MCP-1. More than 90% of cells(evaluated through trypan blue) were viable 1 or 2 days after exposure to ezetimibe. Conclusions: Our results indicate that, in addition to its lipid lowering activity, ezetimibe isable to inhibit the process of adhesion and migration of monocytes in vitro. Blocking of thep44/p42ERK1/2 MAPK signalling pathway seems to play a role in this anti-inflammatory effect (AU)


Assuntos
Animais , Coelhos , Monócitos , Arteriosclerose/tratamento farmacológico , Inflamação/fisiopatologia , Anticolesterolemiantes/farmacocinética , Absorção Intestinal , Modelos Animais de Doenças , Mediadores da Inflamação/análise , Proteínas Quinases
16.
Nutr. hosp ; 26(2): 311-316, mar.-abr. 2011. tab
Artigo em Inglês | IBECS | ID: ibc-94577

RESUMO

Abnormal surface expression of HLA-DR by leukocytes is associated with a poor prognosis in critical care patients. Critical care patients often receive total parenteral nutrition with lipid emulsion (LE). In this study we evaluated the influence of fish oil LE (FO) on human monocyte/macrophage (Mφ) expression of surface HLA-DR under distinct activation states. Mononuclear leukocytes from the peripheral blood of healthy volunteers (n=18) were cultured for 24 hours without LE (control) or with 3 different concentrations (0.1, 0.25, and 0.5%) of the follow LE: a) pure FO b) FO in association (1:1-v/v) with LE composed of 50% medium-chain trygliceride and 50% soybean oil (MCTSO), and c) pure MCTSO. The leukocytes were also submitted to different cell activation states, as determinate by addition time: no INF-γ addition, 18 hours before, or at the time of LE addition. HLA-DR expression on Mφ surface was evaluated by flow cytometry using specific monoclonal antibodies. In relation to controls (for 0.1%, 0.25%, and 0.5%: 100) FO decreased the expression of HLA-DR when added alone [in simultaneously-activated Mφ, for 0.1%: 70 (59 ± 73); for 0.25%: 51 (48 ± 56); and for 0.5%: 52.5 (50 ± 58)] or in association with MCTSO [in simultaneously-activated Mφ, for 0.1%: 50.5 (47 ± 61); for 25%: 49 (45 ± 52); and for 0.5%: 51 (44 ± 54) and in previously-activated Mf, for 1.0%: 63 (44 ± 88); for 0.25%: 70 (41 ± 88); and for 0.5%: 59.5 (39 ± 79)] in culture medium (Friedman p < 0.05). In relation to controls (for 0.1%, 0.25%, and 0.5%: 100), FO did not influence the expression of these molecules on non-activated Mφ [for 0.1%: 87.5 (75±93); for 0.25%: 111 (98 ± 118); and for 0.5%: 101.5 (84 ± 113)]. Results show that parenteral FO modulates the expression of HLA-DR on human Mφ surface accordingly to leukocyte activation state. Further clinical studies evaluating the ideal moment of fish oil LE infusion to modulate leukocyte functions may contribute to a better understanding of its immune modulatory properties (AU)


La expresión anómala del HLA-DR sobre la superficie de los leucocitos se asocia con un pronóstico sombrío en pacientes críticos. A menudo, estos pacientes reciben nutrición parenteral total con una emulsión lipídica (EL). En este estudio, evaluamos la influencia de una EL de aceite de pescado (AP) en la expresión del HLA-DR en la superficie de monocitos/macrófagos humanos (MΦ) bajo diferentes estados de activación. Se cultivaron leucocitos mononucleares de sangre periférica de voluntarios sanos (n = 18) durante 24 horas sin la EL (control) o con 3 concentraciones distintas (0,1, 0,25 y 0,5%) de la siguiente EL: a) AP puro b) AP en asociación con EL (1:1 v/v) compuesta de 50% de triglicéridos de cadena media y 50% de aceite de soja (TCMAS), y c) TCMAS puro. También sometimos a los leucocitos a diferentes estados de activación celular, determinado por INF-γ tiempo de adición: no INF-γ adición 18 horas antes, o en el momento de añadir la EL. La expresión del HLA-DR sobre la superficie de los MΦ se evaluó mediante citometría de flujo utilizando anticuerpos monoclonales específicos. En relación con los controles (para 0,1%, 0,25% y 0,5%: 100) el AP disminuyó la expresión de HLA-DR cuando se añadía solo [en MΦ activados simultáneamente, para 0,1%: 70 (59 ± 73); para 0,25%: 51 (48 ± 56); y para 0,5%: 52.5 (50 ± 58)] o en asociación con TCMAS [en MΦ activados simultáneamente para 0,1%: 50,5 (47 ± 61); para 0,25%:(45 ± 52); y para 0,5%: 51 (44 ± 54) y en MΦ previamente activados para 0,1%: 63 (44 ± 88); para 0,25%: 70 (41 ± 88); y para 0,5%: 59,5 (39 ± 79)] en el medio de cultivo (Friedman p < 0,05). Con respecto a los controles, (para 0,1%, 0,25% y 0,5%: 100), el AP no influyó en la expresión de estas moléculas en MΦ no activados [para 0,1%: 87,5 (75 ± 93); para 0,25%: 111 (98 ± 118); y para 0,5%: 101,5 (84 ± 113)]. Los resultados muestran que el AP parenteral modula la expresión del HLA-DR sobre la superficie de los MΦ humanos en función del estado de activación leucocitaria. Estudios clínicos adicionales que evalúen el momento idóneo de añadir la infusión de EL con aceite de pescado para modular las funciones leucocitarias podrían contribuir a entender mejor sus propiedades inmunomoduladoras (AU)


Assuntos
Humanos , Antígenos HLA-DR/análise , Monócitos , Macrófagos , Óleos de Peixe/metabolismo , Infusões Parenterais , Biotransformação/fisiologia
17.
Reumatol. clín. (Barc.) ; 7(1): 72-76, ene.-feb. 2011.
Artigo em Espanhol | IBECS | ID: ibc-84617

RESUMO

El síndrome de antifosfolípidos (SaF) es una enfermedad autoinmune caracterizada por abortos recurrentes, eventos trombóticos (arteriales o venosos) y hemocitopenias asociadas con títulos altos de aFL séricos. Se han descrito dos presentaciones de SaF: el SaF primario, que se presenta como entidad única y el SaF secundario o asociado principalmente a LEG. Los aFL son un grupo heterogéneo de inmunoglobulinas dirigidas contra diversos componentes o factores proteicos. En 1990, tres grupos de investigadores identificaron a la Beta2GP-I como el principal blanco antigénico de los aFL presentes en los pacientes con SaF. Diversos trabajos han mostrado que existe más de un mecanismo patogénico involucrado en el desarrollo del SaF. Las manifestaciones clínicas mejor documentadas son los abortos recurrentes y las alteraciones trombóticas. Lo anterior se fundamenta en las evidencias observadas in vivo en modelos animales e in vitro causadas por los anticuerpos anti-Beta2GP-I (aBeta2GP-I) de pacientes con SaF o de origen animal. La presente revisión tiene como objetivo mostrar los mecanismos patogénicos que participan en el desarrollo del SaF. Presentamos, además, las evidencias que muestran que los aBeta2GP-I inducen un estado proinflamatorio, proadhesivo y procoagulante (AU)


The antiphospolipid syndrome (APS) is an autoimmune disease characterized by recurrent fetal loss, thrombotic events (arterial or venous) and hemocytopenic disorders associated to high titers of circulating aPL. Two variants of the APS have been described. Primary APS is a clinical entity without evidence of any other autoimmune disease and secondary APS is a clinical disorder mainly associated with Systemic Lupus Erithematosus (SLE). aPL are a widely group of immunoglobulins directed against different components or proteins factors. In 1990 three groups of researchers identified that Beta2GP-I is the mainly antigenic target of aPL in APS patients. There are evidences that show that more than one pathogenic mechanism is involved in the development of the APS. The best documented clinical manifestations associated with the APS are recurrent fetal loss and thrombotic disorders. The latter is based on observations in vivo in animal models and in vitro on the effects caused by aBeta2GP-I antibodies from patients with APS or from animals which cause experimental APS. The objective of the present paper is to show the pathogenic mechanisms that participate in the development of the APS. We also presented evidence that shows that aBeta2GP-I induces pro-inflammatory, pro-adhesive and pro-coagulant disorder (AU)


Assuntos
Humanos , Masculino , Feminino , Anticorpos Antifosfolipídeos/análise , Anticorpos Antifosfolipídeos , Anticorpos Antifosfolipídeos/isolamento & purificação , Doenças Autoimunes/diagnóstico , Citocinas , Educação Médica Continuada/métodos , Educação Médica Continuada/tendências , Anticorpos Antifosfolipídeos/imunologia , Anticorpos Antifosfolipídeos/metabolismo , Monócitos/imunologia , Monócitos/metabolismo , Imunidade Celular/imunologia
18.
Clín. investig. arterioscler. (Ed. impr.) ; 22(4): 136-145, jul.-ago. 2010. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-96639

RESUMO

Introducción La LDL electronegativa (LDL[−]) es una fracción minoritaria de la LDL total que se encuentra en circulación y presenta diferentes propiedades inflamatorias, siendo una de las más relevantes la inducción de citoquinas en células endoteliales y mononucleares. Sin embargo, no se conoce el mecanismo por el cual la LDL(−) ejerce su acción (..) (AU)


Introduction Elecronegative LDL (LDL(−)) is a small fraction of the total circulating LDL and has different inflammatory properties, one of the most important being the induction of cytokines in endotelial cells and monocytes. However, the mechanism by which LDL (−) exercises its action at cellular level is not known. The objective of this study was to evaluate the receptors involved in LDL (−) binding in monocytes, and how the liberation of cytokines (..) (AU)


Assuntos
Humanos , Citocinas/agonistas , LDL-Colesterol/farmacocinética , Receptores Toll-Like/análise , Proteoglicanas/análise , Monócitos/fisiologia , Receptores de Lipopolissacarídeos/fisiologia
19.
Nutr. hosp ; 25(3): 462-467, mayo-jun. 2010. tab
Artigo em Inglês | IBECS | ID: ibc-84727

RESUMO

Abnormal surface expression of HLA-DR by leukocytes is associated with a poor prognosis in critical care patients. Critical care patients often receive total parenteral nutrition with lipid emulsion (LE). In this study we evaluated the influence of fish oil LE (FO) on human monocyte/macrophage (Mf) expression of surface HLA-DR under distinct activation states. Mononuclear leukocytes from the peripheral blood of healthy volunteers (n = 18) were cultured for 24 hours without LE (control) or with 3 different concentrations (0.1, 0.25, and 0.5%) of the follow LE: a) pure FO b) FO in association (1:1 - v/v) with LE composed of 50% medium chain trygliceride and 50% soybean oil (MCTSO), and c) pure MCTSO. The leukocytes were also submitted to different cell activation states, as determinate by INF-γ addition time: no INF-γ addition, 18 hours before, or at the time of LE addition. HLA-DR expression on Mf surface was evaluated by flow cytometry using specific monoclonal antibodies. In relation to controls (for 0.1%, 0.25%, and 0.5%: 100) FO decreased the expression of HLA-DR when added alone [in simultaneously-activated Mf, for 0.1%: 70 (59 ± 73); for 0.25%: 51 (48 ± 56); and for 0.5%: 52.5 (50 ± 58)] or in association with MCTSO [in simultaneously-activated Mf, for 0.1%: 50.5 (47 ± 61); for 25%: 49 (45 ± 52); and for 0.5%: 51 (44 ± 54) and in previously-activated Mf, for 1.0%: 63 (44 ± 88); for 0.25%: 70 (41 ± 88); and for 0.5%: 59.5 (39 ± 79)] in culture medium (Friedman p < 0.05). In relation to controls (for 0.1%, 0.25%, and 0.5%: 100), FO did not influence the expression of these molecules on non-activated Mf [for 0.1%: 87.5 (75 ± 93); for 0.25%: 111 (98 ± 118); and for 0.5%: 101.5 (84 ± 113)]. Results show that parenteral FO modulates the expression of HLA-DR on human Mf surface accordingly to leukocyte activation state. Further clinical studies evaluating the ideal moment of fish oil LE infusion to modulate leukocyte functions may contribute to a better understanding of its immune modulatory properties (AU)


La expresión anormal del HLA-DR en la superficie de los leucocitos se asocia con un pronóstico peor en los enfermos críticos. Estos enfermos a menudo reciben nutrición parenteral total con una emulsión lipídica (EL.) En este estudio evaluamos la influencia de la EL de aceite de pescado (AP) sobre la expresión del HLA-DR de superficie por los monocitos /macrófagos humanos (Mf) en distintos estados de activación. Se cultivaron leucocitos mononucleares de sangre periférica de voluntarios sanos (n = 18) durante 24 horas sin EL (control) o con tres concentraciones diferentes (0,1, 0,25 y 0,5%) de la siguiente EL: a) AP puro b) AP en asociación (1:1 en v/v) con la EL compuesta de un 50% de triglicéridos de cadena media y 50% de aceite de soja (TCMAS), y c) TCMAS puro. Se sometió a los leucocitos a tres estados de activación diferentes, como venía determinado por el tiempo de adición de INF-γ: sin añadir INF-γ, 18 horas antes o en el momento de añadir la EL. La expresión de HLA-DR en la superficie de los Mf se evaluó mediante citometría de flujo empleando anticuerpos monoclonales específicos. En relación con los controles (para 0,1%, 0,25% y 0,5%: 100) el AP disminuyó la expresión de HLA-DR cuando se añadía solo {en Mf activados de forma simultánea, para 0,1%: 70 (59 ± 73); para 0,25%: 51 (48 ± 56) y para 0,5%: 52,5 (50 ± 58)} o en asociación con TCMAS [en Mf activados de forma simultánea, para 0,1%: 50,5 (47 ± 61); para 25%: 49 (45 ± 52); y para 0,5%: 51 (44 ± 54) y en Mf activados previamente, para 1,0%: 63 (44 ± 88); para 0,25%: 70 (41 ± 88); y para 0,5%: 59,5 (39 ± 79)] en medio de cultivo (Friedman p < 0,05.) En relación con los controles (para 0,1%, 0,25% y 0,5%: 100), el AP no influyó en la expresión de estas moléculas en los Mfno activados [para 0,1%: 87,5 (75 ± Ó93); para 0,25%: 111 (98 ± 118); y para 0,5%: 101,5 (84 ± 113)}. Los resultados muestran que el AP parenteral modula la expresión del HLA-DR sobre la superficie de los Mfhumanos en función del estado de activación de los leucocitos. Estudios clínicos adicionales que evalúen el momento ideal de la infusión de la EL con aceite de pescado para modular las funciones leucocitarias podrían contribuir a un mejor conocimiento de sus propiedades inmunomoduladoras (AU)


Assuntos
Adulto , Humanos , Nutrição Parenteral , Emulsões Gordurosas Intravenosas/administração & dosagem , Emulsões Gordurosas Intravenosas/farmacologia , Óleos de Peixe/administração & dosagem , Óleos de Peixe/farmacologia , Antígenos HLA-DR/biossíntese , Macrófagos , Macrófagos/imunologia , Monócitos , Monócitos/imunologia , Células Cultivadas
20.
Rev. clín. esp. (Ed. impr.) ; 209(10): 478-482, nov. 2009. tab
Artigo em Espanhol | IBECS | ID: ibc-74493

RESUMO

Introducción y objetivos: El mixoma es la neoplasia benigna cardíaca más frecuente. El objetivo de este estudio es relacionar los síntomas y los hallazgos en las pruebas complementarias de los pacientes diagnosticados de mixoma con las características macroscópicas del tumor. Material y métodos: Se analizaron de forma retrospectiva en dos hospitales de tercer nivel un total de 30 mixomas cardíacos en los últimos 22 años. En el mismo período se identificaron 5 sarcomas cardíacos. Para las comparaciones se utilizó el test de la ji cuadrado y el test exacto de Fischer. En un paciente con síntomas sistémicos e inflamatorios se determinó la producción de interleucina 6 (IL-6) en células mononucleares de sangre periférica antes y después de la cirugía. Resultados: La distribución de los enfermos fue equitativa para ambos sexos. La edad media fue de 60 años. Las manifestaciones clínicas más prevalentes fueron los síntomas cardíacos (73,3%), seguidos de los síntomas generales (30%) y las manifestaciones embólicas (26,7%). El diagnóstico se realizó mediante ecocardiograma, siendo la localización predominante la aurícula izquierda. Los tumores de mayor tamaño se presentaron en edades avanzadas y se relacionaron más frecuentemente con manifestaciones cardíacas y con más alteraciones radiológicas y electrocardiográficas. Por el contrario, los tumores de menor tamaño y pediculados tuvieron manifestaciones embólicas con mayor asiduidad. No hubo mortalidad postoperatoria aunque sí arritmias transitorias. No se describieron recidivas locales. Se comprobó que los monocitos de sangre periférica contribuyen de forma mayoritaria a la producción de IL-6 en un paciente con síntomas sistémicos. Conclusiones: El mixoma es la neoplasia cardíaca más frecuente. Los síntomas cardíacos son la forma de presentación más común de los mixomas. El diagnóstico se realizó mediante ecocardiografía. El tamaño y la morfología del tumor se relacionan con la edad del paciente y con algunas manifestaciones clínicas y hallazgos de las pruebas complementarias. El tratamiento es quirúrgico y suele ser seguro y curativo (AU)


Introduction: Myxomas are the most common type of benign heart tumors. The aim of this study was to correlate the clinical forms of presentation of cardiac myxoma and complementary laboratory results with the morphological features of the tumor. Materials and methods: We reviewed retrospectively a total of 30 cardiac myxomas seen in 2 institutions after a period of 22 years. In the same period 5 cardiac sarcomas were identified. The Chi-Square test and Fischer's exact test were used to compare the variables. In one patient the IL-6 production by peripherals blood cells before and after surgical tumor resection was evaluated. Results: The patients were evenly distributed between genders. The mean age of this group was 60 years. The most prevalent clinical manifestations were cardiac symptoms (73,3%), constitutional symptoms (30%) and embolisms (26,7%). All cases were diagnosed by transthoracic echocardiography and the most frequent location of the tumor was the left atrium. Larger-diameter myxomas were observed in older patients and correlated with cardiac symptoms, radiological and electrocardiographical abnormalities. Smallerdiameter myxomas presented more frequently embolic phenomenons. There were no deaths during the postoperative period and the principal postoperative complication was transient arrhytmias. There was no evidence of recurrence of the disease. In one patient with systemic manifestations monocytes were observed to contribute to the increased serum levels of IL-6. Conclusions: Myxomas are the most frequent tumors of the heart. The most common initial manifestations were cardiac symptoms. Diagnosis was achieved in all patients by transthoracic echocardiography. The size and macroscopic appearance of the tumor correlated with the age of the patients and some clinical symptoms and laboratory results. Surgical excision was a safe and effective procedure (AU)


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Mixoma/complicações , Mixoma/diagnóstico , Mixoma/epidemiologia , Ecocardiografia/métodos , Ecocardiografia/tendências , Neoplasias Cardíacas/diagnóstico , Neoplasias Cardíacas/cirurgia , Citometria de Fluxo/métodos , Estudos Retrospectivos , Monócitos/patologia , Mixoma/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA